Short description:
Oncolytic Virus
Drug notes:
Also combo Clin2 bladder cancer, combo Clin1 bladder cancer
Long description:
CG Oncology is developing oncolytic immunotherapies to treat patients with advanced bladder cancer. Bladder cancer is the 4th most common form of cancer in men in the US. To address this CG is genetically engineering oncolytic immunotherapies. The therapy has a dual mechanism of action: first, the therapy infects and replicates inside tumor cells causing cell lysis. Secondly, the rupturing of cancer cells releases tumor-derived antigens that stimulates a systemic anti-tumor immune response. CG has 3 active clinical programs with their lead candidate, CG0070, showing remarkable efficacy in bladder cancer patients in their clinical trials.
Jobs:
Senior Scientist, Materials, Science & Technology ... United States|3 days ago
Sr Manager Clinical Supply Chain- Remote, US Based... United States|16 days ago
Medical Science Liaison (MSL) North Central United... Irvine, CA|27 days ago
Senior Director, Health Economics & Outcomes Resea... Irvine, CA|45 days ago
AVP, TECHNICAL OPERATIONS Irvine, CA|61 days ago